**SUPPLEMENTARY MATERIAL**

**Supplementary Table 1.** Baseline patient’s characteristics.

|  |  |
| --- | --- |
| Variable | Value (median ±IQR / %) |
| N | 20 |
| Age (years) | 60.5 (56-70) |
| Sex (%)   * + Male   + Female | 65 (13/20)  35 (7/20) |
| Body Mass Index (median – IQR) | 25.4 (23.6 - 28) |
| Hypertension (%) | 40 (8/20) |
| Diabetes Mellitus (%)   * + HbA1c (median – IQR) | 35 (7/20)  6.1 (5.5-7.6) |
| Creatinine (mg/dl) | 0.79 (0.6 – 1) |
| Previous cardiovascular event (MI, stroke) | 5 (1/20) |
| HCV Genotype 1b (%) | 100 (20/20) |
| Baseline HCV viral load (median, UI/ml) | 1,440,000 (±529,454) |
| Previous HCV treatment with PEG-IFN (%) | 45 (9/20) |
| HCV treatment regimen (%):   * ASV – DCV * SOF – DCV * SOF – LDV | 70 (14/20)  10 (2/20)  20 (4/20) |
| Cirrhosis (% total)   * A * B * C | 80 (16/20)  81.25 (13/16)  18.75 (3/16)  0 (0/16) |
| Basal MELD in patients with cirrhosis (median) | 7.58 (3.9-9.5) |
| Esophageal varices (%) | 55 (11/20) |
| Ascites (%) | 20 (4/20) |
| Hepatic encephalopathy (%) | 10 (2/20) |
| Platelet count (cells/mm3) x 103 | 107 (66-145.5) |
| Albumin (g/dl) | 4.0 (3.8-4.4) |
| SVR with DAA treatment (%) | 90 (18/20) |

**Supplementary Figure 1.** Changes in the lipid panel values at baseline, end of treatment (EOT) and 3 months follow-up (3m FU). Total cholesterol (TC), LDL, HDL, triglycerides, Apolipoprotein A1 and B. (One way ANOVA, ns = non-significant).

![Diagram, schematic

Description automatically generated]()